Clinical Trials

Date: 2021-11-15

Type of information: Publication of results in a medical journal

phase: preclinical

Announcement: publication of results in Neurotherapeutics

Company: Tetraneuron

Product: gene therapy based on E2F4DN

Action mechanism: gene therapy. This gene therapy is based on E2F4DN, a modified variant of E2F4, a crucial protein for neuronal function. This variant cannot be phosphorylated. The blocking of this phosphorylation prevents the start of neuronal tetraploidy, restoring homeostasis and neuronal function in the brain.

Disease: Alzheimer's disease

Therapeutic area: Neurodegenerative diseases


Trial details:

Latest news:

Is general: Yes